DPHL Stock Overview
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Dechra Pharmaceuticals PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£38.70 |
| 52 Week High | UK£38.84 |
| 52 Week Low | UK£24.74 |
| Beta | 0.78 |
| 1 Month Change | 0.55% |
| 3 Month Change | 2.27% |
| 1 Year Change | 35.79% |
| 3 Year Change | 5.91% |
| 5 Year Change | 63.71% |
| Change since IPO | 744.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| DPHL | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.2% | 4.0% | 2.3% |
| 1Y | 35.8% | 0.2% | 0.6% |
Return vs Industry: DPHL exceeded the UK Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: DPHL exceeded the UK Market which returned -6.7% over the past year.
Price Volatility
| DPHL volatility | |
|---|---|
| DPHL Average Weekly Movement | 0.5% |
| Pharmaceuticals Industry Average Movement | 8.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: DPHL has not had significant price volatility in the past 3 months.
Volatility Over Time: DPHL's weekly volatility has decreased from 6% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 2,457 | Ian Page | www.dechra.com |
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases.
Dechra Pharmaceuticals PLC Fundamentals Summary
| DPHL fundamental statistics | |
|---|---|
| Market cap | UK£4.40b |
| Earnings (TTM) | -UK£27.90m |
| Revenue (TTM) | UK£761.50m |
5.8x
P/S Ratio-157.8x
P/E RatioIs DPHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DPHL income statement (TTM) | |
|---|---|
| Revenue | UK£761.50m |
| Cost of Revenue | UK£331.90m |
| Gross Profit | UK£429.60m |
| Other Expenses | UK£457.50m |
| Earnings | -UK£27.90m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 56.42% |
| Net Profit Margin | -3.66% |
| Debt/Equity Ratio | 64.6% |
How did DPHL perform over the long term?
See historical performance and comparison